Related Experiment Video
Updated: Jul 10, 2025
Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
[Subtle and subclinical neurological findings in patients with SARS-CoV-2]
Daniel Arturo Martínez-Piña1, Daniel San Juan-Orta2, Edith González-Guevara3
1Secretaría de Salud, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Servicio de Neurología. Ciudad de México, México.
Background:
There are severe neurological conditions in patients with COVID-19, such as: cerebrovascular disease, Guillain-Barré syndrome, encephalitis, acute hemorrhagic necrotizing encephalopathy and myelitis.
Objective:
We describe that the patient with SARS-CoV 2 with respiratory symptoms has subtle or subclinical neurological manifestations.
Material And Methods:
Observational, cross-sectional, analytical study, which included patients aged 18-65 years with respiratory symptoms and a confirmed diagnosis of COVID-19. Intubated patients with chronic neurodegenerative diseases or pre-existing neurological compromise were excluded. Semiology of the headache and neurological examination were performed; Serum levels of glucose, protein, electrolytes, lactate, C-reactive protein, lactic dehydrogenase, and D-dimer were measured. Cerebrospinal fluid (CSF) analysis and electroencephalogram (EEG) were also performed in patients who accepted the risks.
Results:
A high prevalence of subtle neurological manifestations was found in patients with COVID-19 with only a respiratory clinical picture. Headache, anosmia, dysgeusia, and hypopalesthesia predominated in the early stages, with frequent abnormal findings in the CSF (>70%) and less frequently in the EEG (<20%).
Conclusions:
Headache, anosmia, dysgeusia and hypoesthesia were frequent at the beginning of the infection, together with abnormal findings in CSF and EEG, without other neurological symptoms or neurological disease.
